Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Clinical and Translational Medicine|April 30, 2024
Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trialYuzhou Zhao, Danyang Li, Jing Zhuang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.
Lancet (London, England)|October 22, 2025
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trialZheng Wang, Jia Fan, Shaolai Zhou, et al.
Signal Transduction and Targeted Therapy|March 26, 2024
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 studyXiaofeng Chen, Hao Xu, Xiaobing Chen, et al.
BMC Medicine|May 5, 2023
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV studyJin Li, Shukui Qin, Lu Wen, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II studyXiangrui Meng, Junsheng Wang, Jin Xia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2024
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)Chen Li, Yantao Tian, Yanan Zheng, et al.
Nature Medicine|July 2, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trialJianjun Qin, Liyan Xue, Anlin Hao, et al.
Pageof 7